| Peer-Reviewed

Pulmonary Hypertension and Multiple Myeloma

Received: 8 June 2013     Published: 20 July 2013
Views:       Downloads:
Abstract

The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.

Published in Clinical Medicine Research (Volume 2, Issue 4)
DOI 10.11648/j.cmr.20130204.17
Page(s) 73-76
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2013. Published by Science Publishing Group

Keywords

Multiple Myeloma, Pulmonary Hypertension, Thalidomide

References
[1] GShiue ST, McNally DP. Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. Arch Intern Med. 1988 ;148(3):687-9
[2] Lehtonen J, Kettunen P. Pulmonary hypertension as a dominant clinical picture in a case of amyloidosis and smoldering multiple myeloma. Int J Cardiol. 2007 Jan 31;115(1):e29-30. Epub 2006 Oct 17.
[3] Chinen K , Fujioka Y. Severe pulmonary hypertension caused by smoldering plasma cell myeloma : an autopsy case of POEMS syndrome . Case reports in medicine 2012; doi .10.1155/2012/836893
[4] Dispenzieri A, Kyle RA, Lacy MQ et al . POEMS syndrome : definitions and long-term outcome . Blood 2003; 101: 2496 -2506
[5] Ribadeau-Dumas S, Tillie-Leblond I, Rose C, et al. Pulmonary hypertension associated with POEMS syndrome. Eur Respir J. 1996;9:1760-1762
[6] Rose C, Zandecki M, Copin MC, et al. POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia. 1997;11:1318-1323
[7] Younis TH. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. British Journal of Haematology 121, 191–192, 2003
[8] Antonioli E , Nozzoli C, Gianfaldoni G et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma Ann Oncol (November 2005) 16(11): 1849-1850.
[9] Rostagno C, Ciolli S. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma. Ann Haematol 2006;85:627-8
[10] Dingli D; Utz JP Gertz MA. Pulmonary hypertension in patients with amyloidosis . Chest 2001; 120: 1736-8
[11] Elice F, Fink L, Tricot G, BarlogieB, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitor abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399–405
[12] Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008; 112(9):3582-6.
[13] Zangari M, Saghafifar F, Anaissie E, et al Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187-192.
[14] Corso A, Lorenzi A, Terulla V, et al Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588-591.
[15] Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome: report on two cases and a review of the literature. Medicine. 1980;59:311-322
[16] Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome. Am J Med. 1994;97:543-553
[17] Yaqub S, Moder KG, Lacy MQ . Severe , reveversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyosistis. Mayo Clin Proc 2004; 79: 687-9
[18] Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med. 1998;157:907-911
[19] Feinberg L, Temple D, de Marchena E, Patarca R, Mitrani A. Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature. Crit Rev Oncog. 1999;10:293-302
[20] Paciocco G, Bossone E, Erba H, Rubenfire M. Reversible pulmonary hypertension in POEMS syndrome: another etiology of triggered pulmonary vasculopathy? Can J Cardiol. 2000;16:1007-101
[21] Lesprit P, Authier FJ, Gherardi R, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine. 1996;75:226-232
[22] Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390-1397
[23] Soubrier M, Dubost JJ, Serre AF, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40:786-78
[24] Villa A, Mazzola AA, Ghio S, Martinoli E, Marino P. Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma. Case Rep Oncol. 2011 Sep;4(3):487-9. doi: 10.1159/000333016. Epub 2011 Sep 28
[25] Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematology2004; 89: 826–831.
[26] C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis K. Zervas Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Annals of Oncology 19: 1765–1769, 200
[27] Pepke-Zaba J, Morrell NW. The endothelin system and its role in pulmonary arterial hypertension (PAH). Thorax 2005; 60(6): 443–444.
[28] Steiner MK, Preston IR, Klinger JR, Hill NS. Pulmonary hypertension: invale nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005; 5(3):245–250.
[29] Hattori Y, Shimoda M, Okamoto S et al. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 2005; 128: 885–888.
Cite This Article
  • APA Style

    Carlo Rostagno, Rostagno Perfetto. (2013). Pulmonary Hypertension and Multiple Myeloma. Clinical Medicine Research, 2(4), 73-76. https://doi.org/10.11648/j.cmr.20130204.17

    Copy | Download

    ACS Style

    Carlo Rostagno; Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin. Med. Res. 2013, 2(4), 73-76. doi: 10.11648/j.cmr.20130204.17

    Copy | Download

    AMA Style

    Carlo Rostagno, Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin Med Res. 2013;2(4):73-76. doi: 10.11648/j.cmr.20130204.17

    Copy | Download

  • @article{10.11648/j.cmr.20130204.17,
      author = {Carlo Rostagno and Rostagno Perfetto},
      title = {Pulmonary Hypertension and Multiple Myeloma},
      journal = {Clinical Medicine Research},
      volume = {2},
      number = {4},
      pages = {73-76},
      doi = {10.11648/j.cmr.20130204.17},
      url = {https://doi.org/10.11648/j.cmr.20130204.17},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20130204.17},
      abstract = {The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.},
     year = {2013}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Pulmonary Hypertension and Multiple Myeloma
    AU  - Carlo Rostagno
    AU  - Rostagno Perfetto
    Y1  - 2013/07/20
    PY  - 2013
    N1  - https://doi.org/10.11648/j.cmr.20130204.17
    DO  - 10.11648/j.cmr.20130204.17
    T2  - Clinical Medicine Research
    JF  - Clinical Medicine Research
    JO  - Clinical Medicine Research
    SP  - 73
    EP  - 76
    PB  - Science Publishing Group
    SN  - 2326-9057
    UR  - https://doi.org/10.11648/j.cmr.20130204.17
    AB  - The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.
    VL  - 2
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Sperimental and Clinical Medicine, Critic Area Section, University of Florence, Italy

  • Department of Sperimental and Clinical Medicine, Critic Area Section, University of Florence, Italy

  • Sections